Status:
UNKNOWN
Sphingosine-1-phosphate in Asthma
Lead Sponsor:
Guy's and St Thomas' NHS Foundation Trust
Collaborating Sponsors:
King's College London
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This study is being undertaken in order to enhance our understanding how human airways are being constricted in healthy people and in individuals with asthma. There is an unmet need for identification...
Eligibility Criteria
Inclusion
- Cases (asthmatics) inclusion criteria
- 1\. Physician diagnosed asthma, defined as a clear history of typical symptoms and clear reversibility of the PEF/FEV1 (12% or more) within the past year and/or methacholine PC20 \< 8mg/ml.
- Cases Exclusion criteria
- Pregnancy or lactation
- Moderate / Severe asthma (FEV1/PEF \< 80%of the predicted value at screening)
- Patients with any chronic illness other than asthma and other recognised atopic diseases (eczema, rhinitis) or any other abnormality which in the opinion of the principal investigator might compromise the study findings
- A history of recent (within the past 4 weeks) upper or lower respiratory tract infection
- Patients receiving oral, inhaled or parenteral glucocorticoid therapy (steroid) within the last 4 weeks, long acting relievers (salmeterol, formoterol) and antileukotrienes (montelukast) within last 72 hours.
- Inadequate contraception in women of childbearing age
- Inability to comprehend or comply with the protocol
- Controls inclusion criteria
- 1\. Lifelong absence of asthma symptoms and lung function within the normal range.
- Controls exclusion criteria
- Pregnancy or lactation
- Patients with any chronic illness or any other abnormality which in the opinion of the principal investigator might compromise the study findings
- A history of recent (within the past 4 weeks) upper or lower respiratory tract infection
- Oral, inhaled or parenteral glucocorticoid therapy (steroid) within the last 4 weeks, long acting relievers (salmeterol, formoterol) and antileukotrienes (montelukast) within last 72 hours
- Inadequate contraception in women of childbearing age
- Inability to comprehend or comply with the protocol
Exclusion
Key Trial Info
Start Date :
February 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 22 2022
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04134351
Start Date
February 4 2020
End Date
February 22 2022
Last Update
July 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergy Day Care Unite, Guy's Hospital
London, United Kingdom, SE1 9RT